WASHINGTON, D.C. — The U.S. Department of Transportation has announced a temporary regulatory pivot to address a critical gap in its drug-testing protocols, reverting to mandatory observed urine collections where oral fluid testing was previously required but remains unavailable. This stopgap measure follows the June 1, 2023, rollout of updated testing rules that hit a wall due to the Department of Health and Human Services failing to certify the necessary network of laboratory facilities.

The underlying issue stems from a federal requirement that prohibits oral fluid testing until at least two laboratories—one primary and one for split specimen analysis—receive official HHS certification. Because those facilities have not come online, the DOT acknowledged it is currently impossible for carriers to comply with the newer testing standards. Without this temporary amendment, fleets and safety managers would be left without a legal mechanism to conduct essential drug screenings in specific, high-stakes testing scenarios.

Under the current FMCSA regulations, certain situations—such as return-to-duty tests or instances where a sample was deemed invalid without a medical explanation—require a directly observed collection process. The 2023 rule change initially sought to incorporate oral fluid testing into these high-scrutiny events. The DOT has now confirmed that until the lab infrastructure is ready, employers must continue using observed urine collections to satisfy federal mandates. This approach is explicitly framed as a short-term solution intended to bridge the gap until the HHS-certified lab capacity finally matures.

What This Means for Drivers

CDL-A drivers should expect zero changes to their daily routine regarding standard random or pre-employment drug screens at this time. If you are selected for a return-to-duty test or an observed collection, your carrier will still be utilizing the traditional urine-based process rather than an oral swab. Owner-operator compliance remains tied to existing urine-based testing sites until the DOT officially publishes a notice in the Federal Register declaring that the required oral fluid lab network is fully operational.

Industry Reaction

The delay highlights the ongoing tension between federal policy updates and the practical reality of infrastructure readiness. While the industry largely supports modernizing testing methods to streamline operations, the lack of certified labs has created unnecessary confusion for fleet safety departments. Professional drivers continue to navigate a complex landscape of FMCSA regulations, where even minor administrative delays from federal agencies can have cascading effects on hiring and compliance. For those seeking stability in a changing regulatory environment, staying informed through resources like ustrucker.info remains the best way to track how these shifts impact your eligibility and career path.

Key Points

• The DOT is mandating directly observed urine tests in all cases where oral fluid testing is currently required but impossible to perform.
• This temporary fix remains in effect until one year after the HHS announces the certification of the second necessary oral fluid laboratory.
• The move addresses unforeseen compliance hurdles created by the June 2023 drug-testing rule.
• No oral fluid testing can legally proceed under DOT rules until both a primary and a split-specimen lab receive federal certification.

Looking for a better trucking job? US Trucker's free job-matching service connects CDL-A drivers, OTR drivers, regional drivers, and owner-operators with 500+ top US carriers. Leave your details in the form on this page and a recruiter will call you within one business day. Trucking companies are hiring now.

Photo by Tim Samuel on Pexels